Literature DB >> 11122856

Vaccination for melanoma.

L W Thompson1, L Brinckerhoff, C L Slingluff.   

Abstract

Our knowledge of the immune system has grown tremendously in the 50 years since Coley used bacteria in an attempt to create a vaccine for cancer. The strategy for cancer vaccines has developed in that time as well. Both clinical and laboratory evidence suggests that melanoma is the more immunogenic of solid tumors. If treated early, melanoma can be controlled with surgery, but many patients continue to die from it. With our increased understanding of the immune system's interaction with melanoma, many clinical trials of melanoma vaccines are now underway. Vaccines designed to treat metastatic melanoma have shown some evidence of clinical effectiveness. This article outlines the current status of melanoma vaccination.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11122856     DOI: 10.1007/s11912-000-0021-0

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.945


  76 in total

1.  Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma.

Authors:  E Jäger; M Ringhoffer; M Altmannsberger; M Arand; J Karbach; D Jäger; F Oesch; A Knuth
Journal:  Int J Cancer       Date:  1997-04-10       Impact factor: 7.396

2.  Exploitation of the antibody repertoire of cancer patients for the identification of human tumor antigens.

Authors:  O Türeci; U Sahin; C Zwick; F Neumann; M Pfreundschuh
Journal:  Hybridoma       Date:  1999-02

3.  Active immunization of metastatic melanoma patients with interleukin-4 transduced, allogeneic melanoma cells. A phase I-II study.

Authors:  N Cascinelli; R Foà; G Parmiani; F Arienti; F Belli; M G Bernengo; C Clemente; M P Colombo; A Guarini; M T Illeni
Journal:  Hum Gene Ther       Date:  1994-08       Impact factor: 5.695

4.  Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35) peptide: implications for peptide vaccines.

Authors:  L H Brinckerhoff; V V Kalashnikov; L W Thompson; G V Yamshchikov; R A Pierce; H S Galavotti; V H Engelhard; C L Slingluff
Journal:  Int J Cancer       Date:  1999-10-29       Impact factor: 7.396

5.  Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen.

Authors:  M J Maeurer; S M Gollin; D Martin; W Swaney; J Bryant; C Castelli; P Robbins; G Parmiani; W J Storkus; M T Lotze
Journal:  J Clin Invest       Date:  1996-10-01       Impact factor: 14.808

6.  Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or "self" antigens induce antitumor immunity in vivo.

Authors:  T Tüting; A B DeLeo; M T Lotze; W J Storkus
Journal:  Eur J Immunol       Date:  1997-10       Impact factor: 5.532

7.  Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2.

Authors:  S A Rosenberg; J C Yang; S L Topalian; D J Schwartzentruber; J S Weber; D R Parkinson; C A Seipp; J H Einhorn; D E White
Journal:  JAMA       Date:  1994 Mar 23-30       Impact factor: 56.272

8.  Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens.

Authors:  E Jäeger; H Bernhard; P Romero; M Ringhoffer; M Arand; J Karbach; C Ilsemann; M Hagedorn; A Knuth
Journal:  Int J Cancer       Date:  1996-04-10       Impact factor: 7.396

9.  Identification of human cancers deficient in antigen processing.

Authors:  N P Restifo; F Esquivel; Y Kawakami; J W Yewdell; J J Mulé; S A Rosenberg; J R Bennink
Journal:  J Exp Med       Date:  1993-02-01       Impact factor: 14.307

10.  A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma.

Authors:  J P Dutcher; S Creekmore; G R Weiss; K Margolin; A B Markowitz; M Roper; D Parkinson; N Ciobanu; R I Fisher; D H Boldt
Journal:  J Clin Oncol       Date:  1989-04       Impact factor: 44.544

View more
  3 in total

Review 1.  Reducing primary melanoma mortality.

Authors:  E C Borden
Journal:  Curr Oncol Rep       Date:  2000-07       Impact factor: 5.075

2.  Anal melanoma.

Authors:  Marc Singer; Matthew G Mutch
Journal:  Clin Colon Rectal Surg       Date:  2006-05

Review 3.  Early stage (I, II, III) melanoma.

Authors:  V K Sondak; M I Ross; L M Schuchter
Journal:  Curr Treat Options Oncol       Date:  2001-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.